BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35988573)

  • 1. NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
    Adler AI; Slayen S; Stegenga H; Guo Y; Diaz R; Welton NJ; Westwood N; Doull I; Crawley C
    Lancet Respir Med; 2022 Oct; 10(10):e92-e93. PubMed ID: 35988573
    [No Abstract]   [Full Text] [Related]  

  • 2. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
    Laune Q; Brosseau S
    Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
    Travert C; Tomasini P; Greillier L
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D
    Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
    Wright K
    Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
    Nakajima EC; Vellanki PJ; Larkins E; Chatterjee S; Mishra-Kalyani PS; Bi Y; Qosa H; Liu J; Zhao H; Biable M; Hotaki LT; Shen YL; Pazdur R; Beaver JA; Singh H; Donoghue M
    Clin Cancer Res; 2022 Feb; 28(3):446-451. PubMed ID: 34462287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
    Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
    Front Public Health; 2022; 10():947375. PubMed ID: 35937220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
    Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    Baas P
    J Thorac Oncol; 2022 Jan; 17(1):30-33. PubMed ID: 34930609
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
    Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy.
    Ripley RT; Mansfield AS; Sepesi B; Bueno R; Burt BM
    J Thorac Cardiovasc Surg; 2023 Jan; 165(1):364-368. PubMed ID: 35221030
    [No Abstract]   [Full Text] [Related]  

  • 19. First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
    Yang L; Song X; Zeng W; Zheng Z; Lin W
    Orphanet J Rare Dis; 2023 Oct; 18(1):326. PubMed ID: 37845696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
    Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.